ReviewCurrent oncology reports2022

Triplet Therapy in Melanoma - Combined BRAF/MEK Inhibitors and Anti-PD-(L)1 Antibodies.

Julia R Dixon-Douglas et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.